ImmunityBio (NASDAQ:IBRX) Announces Earnings Results, Misses Expectations By $0.14 EPS

ImmunityBio (NASDAQ:IBRX) posted its quarterly earnings data on Tuesday. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.14), FiscalAI reports. The business had revenue of $51.24 million during the quarter, compared to analyst estimates of $49.70 million.

ImmunityBio Trading Up 0.9%

Shares of IBRX traded up $0.07 during trading hours on Thursday, reaching $7.32. 3,698,989 shares of the company’s stock traded hands, compared to its average volume of 23,623,584. ImmunityBio has a 12 month low of $1.95 and a 12 month high of $12.43. The stock has a market cap of $7.66 billion, a PE ratio of -7.55 and a beta of 0.03. The firm’s 50 day simple moving average is $7.66 and its 200-day simple moving average is $7.64.

Trending Headlines about ImmunityBio

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: ImmunityBio reported record second-quarter net product revenue of $50.7 million, up 92% year over year, while first-half revenue increased 121% to $94.8 million. The results reflect continued commercial uptake of Anktiva and support the company’s growth outlook. ImmunityBio Reports Record Q2 2026 Net Product Revenue
• Positive Sentiment: HC Wainwright maintained a Buy rating and $15 price target, while modestly improving its Q3 2026, Q4 2026 and FY2027 EPS forecasts. The firm projects a return to profitability in later years, including $0.94 EPS in FY2029 and $1.39 EPS in FY2030. HC Wainwright analyst estimates
• Neutral Sentiment: Strong Anktiva sales helped ImmunityBio beat revenue expectations, with reported quarterly revenue of $51.24 million versus a $49.70 million consensus estimate. Upcoming regulatory milestones and continued product adoption remain potential catalysts. IBRX Q2 Earnings and Sales
• Negative Sentiment: The company reported a quarterly loss of $0.22 per share, substantially wider than the $0.08 analyst consensus, which prompted reports of the shares gapping down after earnings. The result highlights continued near-term profitability and execution risk. ImmunityBio Shares Gap Down After Earnings Miss
• Negative Sentiment: HC Wainwright reduced its FY2026 EPS forecast to a loss of $0.40 from $0.28 and trimmed its FY2029 and FY2030 profit estimates slightly. Although the analyst remains bullish, the revisions signal greater near-term cost or investment pressures.

Insider Activity at ImmunityBio

In other ImmunityBio news, Director Barry J. Simon sold 25,000 shares of ImmunityBio stock in a transaction that occurred on Wednesday, June 24th. The shares were sold at an average price of $7.88, for a total transaction of $197,000.00. Following the completion of the sale, the director directly owned 2,802,788 shares in the company, valued at $22,085,969.44. The trade was a 0.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Christobel Selecky sold 159,478 shares of the firm’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $9.02, for a total transaction of $1,438,491.56. Following the sale, the director owned 35,064 shares in the company, valued at approximately $316,277.28. This trade represents a 81.98% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 435,443 shares of company stock valued at $3,918,819 over the last three months. 66.10% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On ImmunityBio

Large investors have recently modified their holdings of the company. Invesco Ltd. grew its position in ImmunityBio by 14.6% during the fourth quarter. Invesco Ltd. now owns 182,836 shares of the company’s stock valued at $362,000 after acquiring an additional 23,353 shares during the last quarter. Corient Private Wealth LLC grew its holdings in shares of ImmunityBio by 69.7% during the 4th quarter. Corient Private Wealth LLC now owns 333,149 shares of the company’s stock valued at $660,000 after purchasing an additional 136,858 shares during the last quarter. EP Wealth Advisors LLC purchased a new position in ImmunityBio in the 4th quarter worth $35,000. Empowered Funds LLC bought a new stake in ImmunityBio in the fourth quarter worth $28,000. Finally, VARCOV Co. purchased a new stake in ImmunityBio during the fourth quarter valued at about $524,000. 8.58% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms recently weighed in on IBRX. HC Wainwright restated a “buy” rating and set a $15.00 price target on shares of ImmunityBio in a research report on Tuesday, June 2nd. D. Boral Capital reaffirmed a “buy” rating and issued a $23.00 price objective on shares of ImmunityBio in a research report on Tuesday, May 5th. BTIG Research reiterated a “buy” rating and issued a $12.00 target price on shares of ImmunityBio in a research note on Thursday, May 21st. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of ImmunityBio in a research report on Friday, July 10th. Six analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $14.20.

About ImmunityBio

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.